Saliva as Alternative Specimen for Measuring Inflammatory Markers Interleukins (IL10, IL-4, and IL-1β) in Association with Disease Severity among COVID-19 Patients

ORIGINAL ARTICLE
Samia M. Ahmed, Tariq E. Elmissbah, Ammar A. Bayoumi, Maha Ibrahim, Elshibli M. Elshibli, Amin O. Abbas, Sannaa M. A. Osman

 
International Journal of Biomedicine. 2023;13(2):241-244.
DOI: 10.21103/Article13(2)_OA6
Originally published June 5, 2023

Abstract: 

Background: Saliva is a specimen that is easily collected by non-invasive means and does not require well-trained staff; it could be helpful in measuring inflammatory markers to determine COVID-19 severity. The aim of this study was to investigate saliva as an alternative specimen for measuring inflammatory markers IL-10, IL-4, and IL-1β among COVID-19 patients in relation to disease severity.
Methods and Results: This cross-sectional study was conducted among COVID-19 patients in a fever clinic, isolated hotels, and hospitals providing care for positive COVID-19 patients and in public health centers for negative control patients in Jeddah, Saudi Arabia. A total of 151 subjects participated in this study, including 101 patients with COVID-19 and 50 healthy controls. Patients with COVID-19 were categorized according to the severity of their symptoms into mild (n=50) and severe cases (n=51). The salivary concentrations of IL-4, IL-10, and IL-1β were measured using sandwich MyBioSource ELISA Test Kits.
The age of the study population ranged from 19 to 70 years old, with a mean age of 43.3±13.0 years. The distribution of the study population showed that more of the patients were men (65[64.4%]) than women (36[35.6%]) (P=0.004). The frequency of severe infection in men was higher than in women (35[68.6%] and 16[31.4%], respectively, P=0.008). The group of severe cases was significantly older than the group of mild cases (47.9±11.03 years and 38.64±13.82 years, respectively, P=0.0007). The volume of saliva was the smallest in severe COVID-19, compared to mild cases and controls (P=0.0000 in all cases). The salivary levels of IL-4, IL-10, and IL-1β were greater in the severe cases than in mild cases and controls (46.14±11.61 pg/mL, 12.86±1.99 pg/mL, and 27.45±11.47 pg/mL versus 19.31±5.72 pg/mL, 7.96±2.12 pg/mL, and 6.59±1.90 pg/mL, respectively; P=0.0000 in all cases). The salivary levels of IL-4 and IL-10 in mild cases were greater than in controls (19.31±5.72 pg/mL and 7.96±2.12 pg/mL versus 15.30±4.36 pg/mL and 6.02±0.89 pg/mL, respectively; P=0.0329 and P=0.000, respectively), but salivary IL-1β levels in mild cases did not differ from controls (6.59±1.90 pg/mL vs. 6.03±2.28 pg/mL, P=0.9129).
Conclusion: Saliva could be used as an alternative sample in measuring IL-10, IL-4, and IL-1β with the suggestion of using IL-10 and IL-4 as markers for predicting disease severity.

Keywords: 
COVID-19 • saliva • IL-4 • IL-10 • IL-1β
References: 
  1. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020 Mar 2;5:6. doi: 10.1186/s41256-020-00135-6. 
  2. Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020 Jul 8;11(1):3410. doi: 10.1038/s41467-020-17240-2.
  3. Grasselli G, Tonetti T, Filippini C, Slutsky AS, Pesenti A, Ranieri VM. Pathophysiology of COVID-19-associated acute respiratory distress syndrome - Authors' reply. Lancet Respir Med. 2021 Jan;9(1):e5-e6. doi: 10.1016/S2213-2600(20)30525-7.
  4. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020 Jul;96:467-474. doi: 10.1016/j.ijid.2020.05.055.
  5. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.
  6. Rojas JM, Avia M, Martín V, Sevilla N. IL-10: A Multifunctional Cytokine in Viral Infections. J Immunol Res. 2017;2017:6104054. doi: 10.1155/2017/6104054.
  7. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020 Oct 1;40:37. doi: 10.1186/s41232-020-00146-3.
  8. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6.
  9. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Jun;127:104370. doi: 10.1016/j.jcv.2020.104370.
  10. Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, Liu ZS. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr. 2020 Jun;16(3):251-259. doi: 10.1007/s12519-020-00354-4.
  11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
  12. Chang Y, Bai M, You Q. Associations between Serum Interleukins (IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10) and Disease Severity of COVID-19: A Systematic Review and Meta-Analysis. Biomed Res Int. 2022 Apr 30;2022:2755246. doi: 10.1155/2022/2755246. 
  13. To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, Lui DH, Ho DT, Hung IF, Chan KH, Yuen KY. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect. 2017 Jun 7;6(6):e49. doi: 10.1038/emi.2017.35.
  14. To KKW, Yip CCY, Lai CYW, Wong CKH, Ho DTY, Pang PKP, Ng ACK, Leung KH, Poon RWS, Chan KH, Cheng VCC, Hung IFN, Yuen KY. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin Microbiol Infect. 2019 Mar;25(3):372-378. doi: 10.1016/j.cmi.2018.06.009.
  15. Slavish DC, Graham-Engeland JE, Smyth JM, Engeland CG. Salivary markers of inflammation in response to acute stress. Brain Behav Immun. 2015 Feb;44:253-69. doi: 10.1016/j.bbi.2014.08.008.
  16. Galhardo LF, Ruivo GF, de Oliveira LD, Parize G, Santos SSFD, Pallos D, Leão MVP. Inflammatory markers in saliva for diagnosis of sepsis of hospitalizes patients. Eur J Clin Invest. 2020 May;50(5):e13219. doi: 10.1111/eci.13219.
  17. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S, Yang JK. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020 Apr 29;8:152. doi: 10.3389/fpubh.2020.00152.
  18. Boddington NL, Charlett A, Elgohari S, Byers C, Coughlan L, Vilaplana TG, Whillock R, Sinnathamby M, Panagiotopoulos N, Letley L, MacDonald P, Vivancos R, Edeghere O, Shingleton J, Bennett E, Cottrell S, McMenamin J, Zambon M, Ramsay M, Dabrera G, Saliba V, Bernal JL. Epidemiological and clinical characteristics of early COVID-19 cases, United Kingdom of Great Britain and Northern Ireland. Bull World Health Organ. 2021 Mar 1;99(3):178-189. doi: 10.2471/BLT.20.265603.
  19. Abohamr SI, Abazid RM, Aldossari MA, Amer HA, Badhawi OS, Aljunaidi OM, Alzarzour SH, Saadeddin HM, Bhat FA, Elsheikh E. Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia. Saudi Med J. 2020 Nov;41(11):1217-1226. doi: 10.15537/smj.2020.11.25495.
  20. Luo H, Liu S, Wang Y, Phillips-Howard PA, Ju S, Yang Y, Wang D. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: a retrospective, multicentre cohort study. BMJ Open. 2020 Oct 5;10(10):e039887. doi: 10.1136/bmjopen-2020-039887.
  21. Fathi Y, Hoseini EG, Atoof F, Mottaghi R. Xerostomia (dry mouth) in patients with COVID-19: a case series. Future Virol. 2021;16(5). doi:  10.2217/fvl-2020-0334.
  22. Freni F, Meduri A, Gazia F, Nicastro V, Galletti C, Aragona P, Galletti C, Galletti B, Galletti F. Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol. 2020 Sep-Oct;41(5):102612. doi: 10.1016/j.amjoto.2020.102612. 
  23. Fantozzi PJ, Pampena E, Di Vanna D, Pellegrino E, Corbi D, Mammucari S, Alessi F, Pampena R, Bertazzoni G, Minisola S, Mastroianni CM, Polimeni A, Romeo U, Villa A. Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19. Am J Otolaryngol. 2020 Nov-Dec;41(6):102721. doi: 10.1016/j.amjoto.2020.102721. 
  24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. 
  25. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020 Sep;133:155151. doi: 10.1016/j.cyto.2020.155151.
  26. Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G, Zhu P, Yang G, Xie X. Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021 Sep;75(9):e14462. doi: 10.1111/ijcp.14462.

Download Article
Received March 27, 2023.
Accepted April 30, 2023.
©2023 International Medical Research and Development Corporation.